Muveddet Rezzan Ataman

Muveddet Rezzan Ataman

Auto-generated profile, based on publicly available information

Muveddet Rezzan Ataman

ISTANBUL UNIVERSITY-CERRAHPASA, CERRAHPAŞA SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2021 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
AMAhmet Murt
Ahmet Murt
TTTuba Ozkan Tekin
Tuba Ozkan Tekin
SGSuleyman Sami Guzel
Suleyman Sami Guzel
SOSercan Olcar
Sercan Olcar
ASAyse Salihoglu
Ayse Salihoglu
MAMuveddet Rezzan Ataman
Muveddet Rezzan Ataman

12 June 2023 in Dicle Tıp Dergisi
Verified
Journal Article
Open access
PDF file
AMAhmet Murt
Ahmet Murt
MAMehmet Riza Altiparmak
Mehmet Riza Altiparmak
HDHarika Öykü Dinç
Harika Öykü Dinç
SYSerkan Yalin
Serkan Yalin
MMMeral Meşe
Meral Meşe
MAMuveddet Rezzan Ataman
Muveddet Rezzan Ataman
Background: As hemodialysis patients are among the vulnerable groups for severe COVID-19, proper vaccination of these patients is quite important. However vaccine responsiveness is generally reduced in hemodialysis patients and strategies should be developed to maintain protection in the long term. Objectives: This study aimed to analyse the changes in antibody levels of SARS-CoV-2 vaccinated hemodialysis patients after six months and to compare the effectiveness of inactivated and mRNA vaccines. Methods: Eighty-five hemodialysis patients were followed up for six months after their initial vaccinations for SARS-CoV-2. Persistence of humoral responses were compared between patients who got inactivated or mRNA vaccines and also between patients who received a booster dose and those who didn’t. SARS-CoV-2 antibody titers were measured by a commercial test that measures IgG antibodies toward the receptor-binding domain of spike protein. Results: Seropositivity that was achieved by initial vaccination dropped abruptly by 6 months. Patients who received a booster dose had significantly higher antibody levels than those who didn’t (1120,8 ± 983,3 AU/mL vs 313,3 ± 435,3 AU/mL respectively; p<0,001) and higher seropositivity as well (88% vs 65%). Seropositivity with mRNA vaccine at the end of 6th month was 81,8% while this decreased to 50% for inactivated vaccine. Patients who received mRNA vaccine initially or as the third dose could maintain 88,4% of seropositivtiy and this was higher than other patients who have just got inactivated vaccine (p=0,013). Conclusion: Humoral immune response by SARS-CoV-2 vaccines is not very stable in hemodialysis patients and planning the booster doses should not be delayed. mRNA vaccines have better immunogenicity than inactivated vaccines.